Stocks and Investing Stocks and Investing
Tue, November 7, 2023

David Lebowitz Initiated (BBIO) at Strong Buy and Held Target at $42 on, Nov 7th, 2023


Published on 2024-10-28 07:23:29 - WOPRAI, David Lebowitz
  Print publication without navigation


David Lebowitz of Citigroup, Initiated "BridgeBio Pharma, Inc." (BBIO) at Strong Buy and Held Target at $42 on, Nov 7th, 2023.

David has made no other calls on BBIO in the last 4 months.



There are 6 other peers that have a rating on BBIO. Out of the 6 peers that are also analyzing BBIO, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Eun Yang of "Jefferies" Downgraded from Strong Buy to Hold and Increased Target to $33 on, Tuesday, July 18th, 2023


These are the ratings of the 5 analyists that currently disagree with David


  • Josh Schimmer of "Cantor Fitzgerald" Initiated at Buy and Held Target at $50 on, Tuesday, October 24th, 2023
  • Salim Syed of "Mizuho" Reiterated at Strong Buy and Held Target at $60 on, Monday, August 28th, 2023
  • Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $38 on, Thursday, August 17th, 2023
  • Dane Leone of "Raymond James" Maintained at Buy with Increased Target to $46 on, Tuesday, July 18th, 2023
  • Paul Choi of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $50 on, Tuesday, July 18th, 2023
Contributing Sources